Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Immutep Ltd IMMP

Healthcare Biotechnology
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also... see more

Current News (NDAQ:IMMP)

Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

GlobeNewswire 3 days ago

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire 9 days ago

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

GlobeNewswire November 13, 2025

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

GlobeNewswire November 3, 2025

Immutep Quarterly Activities Report Q1 FY26

GlobeNewswire October 29, 2025

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

GlobeNewswire October 20, 2025

Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

GlobeNewswire October 20, 2025

Immutep Announces Successful Completion of FDA Project Optimus Requirements

GlobeNewswire October 13, 2025

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire October 9, 2025
View More News ››

Opinion & Analysis (NDAQ:IMMP)

Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'

Streetwise Reports February 7, 2018
View More Opinion ››

Bullboard Posts (NDAQ:IMMP)

It was a buy for me today,play it again Sam.

I played this one about 5 years ago,and it was time for me to do it again,for it should be a nice triple your money for me with this one...
coolfooldumbguy - July 15, 2024

it's a buy today for me

at this low price,taking a chance,so glta.
coolfooldumbguy - March 22, 2019
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp., an exploration stage company, acquires, explores, and develops natural resource properties ...
View More »